Efficacy and safety of liraglutide in patients with patients with an ileal pouch-anal anastomosis and chronic high bowel frequency: A placebo-controlled, crossover, proof of concept study

Hans Herfarth; Millie D Long; Jonathan J Hansen; Chelsea Anderson; Emily Ba English; John B Buse; Edward L Barnes

doi:10.14309/ajg.0000000000002801

Efficacy and safety of liraglutide in patients with patients with an ileal pouch-anal anastomosis and chronic high bowel frequency: A placebo-controlled, crossover, proof of concept study

Am J Gastroenterol. 2024 Apr 12. doi: 10.14309/ajg.0000000000002801. Online ahead of print.

Authors

Hans Herfarth¹, Millie D Long¹, Jonathan J Hansen¹, Chelsea Anderson¹, Emily Ba English¹, John B Buse², Edward L Barnes¹

Affiliations

¹ Division of Gastroenterology and Hepatology, University of North Carolina.
² Division of Endocrinology, University of North Carolina.

PMID: 38668926
DOI: 10.14309/ajg.0000000000002801

Abstract

Introduction: After colectomy with ileo-anal pouch anastomosis (IPAA), many patients develop high bowel frequency (BF) refractory to antimotility agents despite normal IPAA morphology. Low circulating levels of glucagon-like protein-1 (GLP-1), a modulator of gastroduodenal motility, have been reported after colectomy.

Methods: Double-blind crossover study of 8 IPAA patients with refractory high BF treated with daily administration of the GLP-1 receptor agonist (GLP-1-RA) liraglutide or placebo.

Results: Liraglutide, but not placebo, reduced daily BF by more than 35% (P<0.03).

Discussion: Larger randomized controlled studies are warranted to delineate the treatment potential of GLP-1RA's in IPAA patients suffering from non-inflammatory high BF.